PDF herunterladen
Homeopathy 2021; 110(04): 263-270
DOI: 10.1055/s-0041-1726009
Original Research Article

Preparation and Standardization of Nosodes Sourced from Klebsiella Pneumoniae, Salmonella Typhi, Neisseria Gonorrhoeae and Candida Albicans Strains

Renuka Munshi
1   Department of Clinical Pharmacology, TNMC and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India
,
Gitanjali Talele
2   Research Department, Life Force Foundation Trust, Mumbai, Maharashtra, India
,
Rajesh Shah
2   Research Department, Life Force Foundation Trust, Mumbai, Maharashtra, India
› Institutsangaben Funding None.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Background Homeopathic nosodes prepared from organisms and pathological tissues have shown biological effects, encouraging more research. There is a need to develop some new nosodes systematically and to re-make others that were developed over a century ago. In our program of work on nosodes, the bacterial strains Klebsiella pneumoniae (BAA 2146), Salmonella typhi and Neisseria gonorrhoeae (ATCC 43069), and the single-celled fungus Candida albicans (24433, 26790, and 60193) have been identified for preparation.

Materials and Methods The systematic and scientific method of preparation of nosodes includes identification, culture, quantification, characterization, preparation, and standardization. Under laminar flow, a suspension of respective bacterial and fungal cells (20 billion cells/mL) was processed as per the Homoeopathic Pharmacopoeia of India (HPI). Culture tests, sterility tests and molecular testing (polymerase chain reaction) were performed to establish the absence of contamination, live organisms and DNA material.

Results K. pneumoniae, S. typhi (single, bivalent, or polyvalent), N. gonorrhoeae, and C. albicans nosodes (single and polyvalent) were sourced and prepared from different strains of respective cultures. The nosode preparations were processed by serial dilution and potentization, normally following the HPI guidelines. Molecular test results showed the absence of live organisms or DNA material; culture and sterility test results demonstrated the safety profile of the potentized nosodes.

Conclusion K. pneumoniae, S. typhi, N. gonorrhoeae and C. albicans nosodes were successfully prepared. Their therapeutic potential may now be evaluated.

Keywords

Klebsiella pneumonia - Salmonella typhi - Neisseria gonorrhoeae - Candida albicans - nosode - potentization - homeopathy

Highlights

• In the series of work on nosodes, the bacterial strains of Klebsiella pneumoniae (BAA 2146), Salmonella typhi, Neisseria gonorrhoeae (ATCC 43069) and the fungus Candida albicans (24433, 26790, and 60193) were identified.


• A systematic, standardized and scientific method of preparation of nosodes was documented.


• Safety of nosodes in 30c potency using sterility, culture and molecular tests was established.


Authors' Contributions

Renuka Munshi[1] provided the laboratory facility and contributed to the laboratory work and manuscript review. Gitanjali Talele[2] contributed to laboratory work and manuscript writing. Rajesh Shah[3] was the principal investigator and inventor of the drugs; he also conceptualized the study and contributed to laboratory work supervision, and manuscript writing.


Supplementary Material



Publikationsverlauf

Eingereicht: 31. Juli 2020

Angenommen: 21. Dezember 2020

Artikel online veröffentlicht:
09. Juni 2021

© 2021. Faculty of Homeopathy. This article is published by Thieme.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Homeopathic Pharmacopoeia of India. 1st ed.. 4th Vol. New Delhi: Ministry of Health, Government of India; 1983: 136-137
    Google Scholar
  • 2 Shah R. Clinical trial for the evaluation of a human immunodeficiency virus nosode in the treatment for human immunodeficiency virus-infected individuals. Indian J Res Homoeopathy 2015; 9: 25-33
    CrossrefPubMedGoogle Scholar
  • 3 Shah R, Hepatitis C. Hepatitis C nosode: the preparation and homeopathic pathogenetic trial. Homeopathy 2013; 102: 207-214
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Joshi S, Mukerjee S, Vaidya S, Talele G, Chowdhary A, Shah R. Preparation, standardization and in vitro safety testing of Mycobacterium nosodes (Emtact-polyvalent nosode). Homeopathy 2016; 105: 225-232
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 5 Joshi S, Munshi R, Talele G, Shah R. An experimental in vitro study to evaluate the antimalarial activity of select homeopathy preparations. Int J Med Health Res 2017; 8: 9
    PubMedGoogle Scholar
  • 6 Shah R. Preparation and standardization of Human papillomavirus (HPV) (Genotype 6) nosode. Int J High Dilution Res 2019; 18: 13-18
    CrossrefPubMedGoogle Scholar
  • 7 Allen HC. The Materia Medica of the Nosodes. With Provings of the X-ray. New Delhi: Jain Publishers; 1988: 544
    Google Scholar
  • 8 Khuda-Bukhsh AR, Mondal J, Shah R. Therapeutic potential of HIV nosode 30c as evaluated in A549 lung cancer cells. Homeopathy 2017; 106: 203-213
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Shah R. Clinical trial for the evaluation of a Hep C nosode in the treatment for Hepatitis C (HCV) positive participants. J Altern Complement Med 2016; 22: 197-203
    CrossrefPubMedGoogle Scholar
  • 10 Boericke W. Pocket Manual of Homeopathic Materia Medica. 9th ed.. New Delhi: Jain Publishers; 1981: 511
    Google Scholar
  • 11 Julian OA. Materia Medica of Nosodes with Repertory. Treatise on Dynamised Micro-Immunotherapy. Part II: Materia Medica of Biotherapic Nosodes. New Delhi: Jain Publishers; 2003: 452
    Google Scholar
  • 12 Health Canada. Drugs and Health Products: Nosodes. Accessed June 28, 2019 at: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=nosodes&lang=eng
    PubMedGoogle Scholar
  • 13 Julian OA. Materia Medica of Nosodes with Repertory. Treatise on Dynamised Micro-Immunotherapy. Part I: Isopathic Concretology; Part II: Materia Medica of Biotherapic Nosodes; Part III: Repertory (Translated from original French by Rajkumar Mukherji). 1st Indian ed.. New Delhi: Jain Publishers; 1984: 237 , 383, 431
    Google Scholar
  • 14 Drugs and Health Products—Nosodes. Health Canada; 2015. . Accessed July 19, 2019 at: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=nosodes&lang=eng
    Google Scholar
  • 15 Kurylo E. Etymologia: Neisseria . Emerg Infect Dis 2016; 22: 1141
    CrossrefPubMedGoogle Scholar
  • 16 Allen HC. Materia Medica of Nosodes with X-ray Provings. New Delhi: Jain Publisher; 1988: 295
    Google Scholar
  • 17 Hering C. The Guiding Symptoms of Our Materia Medica. Vol. 7. New Delhi: Jain Publishers; 1989: 292-324
    Google Scholar
  • 18 Whole Health Now's Biography Database of Over 150 Homeopaths Past & Present. Samuel Swan, MD. Accessed August 12, 2019 at: http://www.wholehealthnow.com/bios/samuel-swan.html
    PubMedGoogle Scholar
  • 19 Dr. Willmar Schwabe, India.. Medorrhinum CH. . Accessed August 12, 2019 at: https://www.schwabeindia.com/3055-medorrhinum.html
    PubMed
  • 20 Julian OA. Materia Medica of Nosodes with Repertory Treatise on Dynamised Micro-Immunotherapy, Part II Materia Medica of Biotherapic Nosodes. Translated from Original French by Rajkumar Mukherji. 1st Indian ed.. New Delhi: Jain Publishers; 1984: 351
    Google Scholar
  • 21 Homoeopathic Pharmacopoeia of the United States. Guidelines for Manufacturing Homeopathic Medicines: Attenuations from microscopic fungal raw materials. Accessed September 5, 2019 at: http://www.hpus.com/Draft-Guidelines-for-Manufacturing-Homeopathic-Medicines.pdf
    PubMedGoogle Scholar
  • 22 Shah R. Standardization of the potentizing machine and quantification of the impact of potentization. Indian J Res Homoeopathy 2016; 10: 126-132
    CrossrefPubMedGoogle Scholar
  • 23 Singh GN. Indian Pharmacopoeia. New Delhi: The Indian Pharmacopoeia Commission Ministry of Health and Family Welfare, Government of India; 2010: 57-58
    Google Scholar
  • 24 Hering C. The Guiding Symptoms of Our Materia Medica. Reprint.. Vol. 8. New Delhi: B. Jain Publishers; 1989: 538
    Google Scholar
  • 25 Allen TF. The Encyclopedia of Pure Materia Medica. Vol. 8. New Delhi: Jain Publishers; 1988: 164
    Google Scholar
  • 26 Allen HC. The Materia Medica of the Nosodes. With Provings of the X-ray. New Delhi: Jain Publishers; 1988: 23
    Google Scholar
  • 27 Allen HC. The Materia Medica of the Nosodes. With Provings of the X-ray. New Delhi: Jain Publishers; 1988: 139
    Google Scholar
  • 28 Allen HC. The Materia Medica of the Nosodes. With Provings of the X-ray. New Delhi: Jain Publishers; 1988: 1
    Google Scholar
  • 29 Allen HC. The Materia Medica of the Nosodes. With Provings of the X-ray. New Delhi: Jain Publishers; 1988: 494
    Google Scholar
  • 30 Lin TH, Huang SH, Wu CC. et al. Inhibition of Klebsiella pneumoniae growth and capsular polysaccharide biosynthesis by Fructus Mume. Evid Based Complement Alternat Med 2013; 2013: 621701
    PubMedGoogle Scholar
  • 31 Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev 2016; 80: 629-661
    CrossrefPubMedGoogle Scholar
  • 32 Reis RS, Horn F. Enteropathogenic Escherichia coli, Samonella, Shigella and Yersinia: cellular aspects of host-bacteria interactions in enteric diseases. Gut Pathog 2010; 2: 8
    CrossrefPubMedGoogle Scholar
  • 33 Galanos C, Freudenberg MA. Bacterial endotoxins: biological properties and mechanisms of action. Mediators Inflamm 1993; 2: S11-S16
    CrossrefPubMedGoogle Scholar
  • 34 Todar's Online Book of Bacteriology. Pathogenic Neisseriae: Gonorrhea, Neonatal Ophthalmia, and Meningococcal Meningitis. Virulence factors. P.3. Accessed July 16, 2019 at: http://textbookofbacteriology.net/neisseria_3.html
    PubMedGoogle Scholar
  • 35 Heads of Medicines Agencies. Homeopathic Medicinal Products Working Group. Guidance on Module 3.2.S for Nosodes. Accessed July 16, 2019 at: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2_GUIDANCE_ON_MODULE_3.2.S_for_NOSODES.pdf
    PubMedGoogle Scholar
  • 36 World Health Organization. WHO Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. WHO Technical Report, Series No. 924; 2004: 150-225
    PubMedGoogle Scholar